United Therapeutics (UTHR) CFO details stock option exercise and sales

Rhea-AI Filing Summary

United Therapeutics Corporation’s CFO and Treasurer reported an option exercise and related share sales. On December 15, 2025, the executive exercised stock options for 3,517 shares of common stock at an exercise price of $146.03 per share and acquired those shares.

On the same date, the executive sold United Therapeutics common stock in multiple open-market transactions, with disclosed weighted average sale prices including $491.525 and $500.303 per share. After these transactions, the executive directly beneficially owns 8,142 shares of United Therapeutics common stock.

The option exercise and subsequent sales were carried out pursuant to a Rule 10b5-1 trading plan entered into on August 5, 2025. The report also corrects a prior administrative error by now including 24 shares acquired on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan in the executive’s reported holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M(1)		3,517	A	$146.03	11,659(2)	D
Common Stock	12/15/2025		S(1)		160	D	$491.525(3)	11,499	D
Common Stock	12/15/2025		S(1)		840	D	$492.8071(4)	10,659	D
Common Stock	12/15/2025		S(1)		561	D	$493.7042(5)	10,098	D
Common Stock	12/15/2025		S(1)		360	D	$495.0159(6)	9,738	D
Common Stock	12/15/2025		S(1)		520	D	$495.9016(7)	9,218	D
Common Stock	12/15/2025		S(1)		200	D	$496.974(8)	9,018	D
Common Stock	12/15/2025		S(1)		395	D	$498.0887(9)	8,623	D
Common Stock	12/15/2025		S(1)		240	D	$499.3132(10)	8,383	D
Common Stock	12/15/2025		S(1)		241	D	$500.303(11)	8,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$146.03	12/15/2025		M(1)			3,517	03/15/2020	03/15/2027	Common Stock	3,517	$0.00	0.00	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025.

2. The amount of common stock beneficially owned by the Reporting Person in the Reporting Person's Form 4s filed November 5, 12 and 18, 2025 did not include 24 shares acquired by the Reporting Person on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan, which error caused the reporting person's common stock ownership to be underreported by 24 shares on such Form 4s. The amount of common stock beneficially owned by the Reporting Person in this Form 4 includes such shares.

3. This transaction was executed in multiple trades at prices ranging from $491.19 to $491.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $492.28 to $493.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $493.35 to $494.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $494.52 to $495.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $495.52 to $496.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $496.59 to $497.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $497.60 to $498.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $498.88 to $499.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $499.92 to $500.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did United Therapeutics (UTHR) report for December 15, 2025?

The CFO and Treasurer of United Therapeutics Corporation exercised stock options for 3,517 shares of common stock at an exercise price of $146.03 per share and then sold shares in multiple open-market transactions on December 15, 2025.

At what prices did the United Therapeutics (UTHR) CFO sell shares?

The executive sold United Therapeutics common stock in several trades with disclosed weighted average sale prices including $491.525, $495.9016 and $500.303 per share, with each transaction’s price range described in the report.

How many United Therapeutics (UTHR) shares does the CFO own after these transactions?

Following the reported option exercise and share sales, the CFO and Treasurer directly and beneficially owns 8,142 shares of United Therapeutics common stock.

Were the United Therapeutics (UTHR) insider trades made under a Rule 10b5-1 plan?

Yes. The filing states that the exercise of stock options and subsequent sale of shares on December 15, 2025 were made pursuant to a Rule 10b5-1 trading plan that the reporting person entered into on August 5, 2025.

What correction to prior United Therapeutics (UTHR) insider ownership was disclosed?

The report explains that prior forms filed on November 5, 12 and 18, 2025 inadvertently omitted 24 shares acquired on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan. Those 24 shares are now included in the reported beneficial ownership.

What type of derivative security did the United Therapeutics (UTHR) executive exercise?

The executive exercised a stock option covering 3,517 shares of United Therapeutics common stock, with a conversion or exercise price of $146.03 per share and an expiration date of March 15, 2027.